Semaglutide is a GLP-1 receptor agonist—a medication that mimics a hormone your body naturally produces. It was originally developed for Type 2 diabetes but became a breakthrough weight loss treatment when clinical trials showed dramatic results.
Average weight loss in trials
1x
Weekly injection
86%
Lost 5%+ body weight
How Does It Work?
Semaglutide works through four main pathways:
1. Brain signals: It acts on your hypothalamus to reduce hunger signals and increase satiety signals. You feel genuinely satisfied with less food.
2. Slower digestion: Food stays in your stomach longer, creating a prolonged feeling of fullness after meals.
3. "Food noise" reduction: Many users report that the constant mental chatter about food—planning meals, fighting cravings—goes quiet. This is often described as the most life-changing effect.
4. Blood sugar regulation: It helps your body release insulin more effectively, keeping blood sugar stable and reducing energy crashes.
Clinical Trial Results
The STEP trials established semaglutide's effectiveness:
Trial
Population
Result
STEP 1
Adults without diabetes
14.9% weight loss vs 2.4% placebo
STEP 2
Adults with Type 2 diabetes
9.6% weight loss vs 3.4% placebo
STEP 5
2-year follow-up
15.2% maintained at 2 years
STEP TEENS
Adolescents 12-17
16.1% BMI reduction
Dosing Schedule
Semaglutide follows a titration schedule—you start low and increase gradually:
Weeks 1-4: 0.25 mg (introduction dose)
Weeks 5-8: 0.5 mg (still building up)
Weeks 9-12: 1.0 mg (effects start increasing)
Weeks 13-16: 1.7 mg (near-therapeutic)
Week 17+: 2.4 mg (full maintenance dose)
Important: The first 8 weeks are for adjustment, not results. Don't panic if you don't see dramatic changes at 0.25 or 0.5 mg—that's expected.
Side Effects
Most common (and usually temporary):
Nausea: Affects many users, especially early on. Usually improves after a few weeks.
Constipation: Slower digestion means slower bowel movements.
Fatigue: Common during the first few weeks as your body adjusts.
Injection site reactions: Minor redness or itching, resolves quickly.
Serious risks (rare): Pancreatitis, gallbladder issues, and a black-box warning about thyroid C-cell tumors (observed in rodent studies). Anyone with personal or family history of medullary thyroid cancer should not take semaglutide.
Who Should Take Semaglutide?
Good candidates:
BMI 30+ (obesity)
BMI 27+ with weight-related conditions
Struggled with diet/exercise alone
Ready for a long-term approach (this isn't a quick fix)
Not appropriate for:
Pregnant or breastfeeding individuals
History of medullary thyroid cancer or MEN2
History of severe pancreatitis
Type 1 diabetes
Semaglutide vs Tirzepatide
Tirzepatide (Zepbound/Mounjaro) is the newer option, targeting two receptors instead of one. In head-to-head trials, tirzepatide produced about 47% more weight loss. However, semaglutide is more affordable (especially compounded), has more long-term safety data, and works extremely well for most people.
Many people start with semaglutide and only consider switching if they plateau.